Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that exist with the integration of recently approved and emerging targeted therapies into the modern care of patients with NSCLC. Better grasp the oncogenic role of different genomic alterations and the associated biomarker tests for capturing them to enable the most appropriate selection of targeted therapies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC; Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC; and Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials